Company intelligence / Profile preview

Cordio Medical

Or Yehuda, Tel Aviv District, Israelcordio-med.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Cordio Medical’s HearO™ app uses proprietary AI algorithms to analyze voice samples from CHF patients via smartphone, enabling early detection of fluid accumulation and impending decompensation. Clinical studies have shown up to 82% success rate in predicting heart failure events up to 22 days before occurrence. The technology has been validated in Israel and the U.S., with pilot programs underway with AstraZeneca and Spanish hospitals.

Therapeutic areas: Infectious DiseasesCardiovascular
Modalities: DeviceNon-pharmacological therapyDigital health solution
Industry: Digital Health Medical Devices

Partnerships

AstraZeneca (pilot program for CHF digital management)Bellvitge University Hospital—clinical pilot site

Beyond the preview

Go deeper on Cordio Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cordio Medical.

Explore the full profile